NCT00543010

Brief Summary

A study to evaluate the cardiac and metabolic effects of MK0767 in patients with Type 2 Diabetes. This is an early phase trial and some specific protocol information is in progress and not publicly available at this time. (Full information is available to trial participants).

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
247

participants targeted

Target at P25-P50 for phase_3 diabetes-mellitus-type-2

Timeline
Completed

Started Nov 2002

Shorter than P25 for phase_3 diabetes-mellitus-type-2

Status
terminated

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2002

Completed
1 year until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2003

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2003

Completed
3.9 years until next milestone

First Submitted

Initial submission to the registry

October 5, 2007

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 12, 2007

Completed
Last Updated

June 12, 2015

Status Verified

June 1, 2015

Enrollment Period

1 year

First QC Date

October 5, 2007

Last Update Submit

June 11, 2015

Conditions

Diabetes Mellitus, Type 2

Interventions

MK0767DRUG

Eligibility Criteria

Age21 Years - 80 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • You are taking at least one medication for high blood sugar
  • Age 21 to 80

You may not qualify if:

  • History of Type 1 Diabetes Mellitus
  • Currently on estrogen replacement therapy regimen
  • Currently on a weight loss program with ongoing weight loss or taking medications for weight loss
  • Having surgery 30 days before starting the study
  • Have taken any other investigational drug in the past 90 days
  • Have Hepatitis B or C
  • Active liver or gallbladder disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

MK0767

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Study Officials

  • Medical Monitor

    Merck Sharp & Dohme LLC

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 5, 2007

First Posted

October 12, 2007

Study Start

November 1, 2002

Primary Completion

November 1, 2003

Study Completion

November 1, 2003

Last Updated

June 12, 2015

Record last verified: 2015-06